Skip to content

MAXPHARMA

Active Public limited companyfounded 2000active for 26 yearsSteenweg op Waver 736, 1040 EtterbeekKBO/BCE: BE 0471.830.863 subsidiary of
MAXPHARMA
Follow ReportCompare

Overview

Lifetime

20 annual accounts with figures on one time axis, 26 filings since 2000
peak €225,463 (2021)
€113,032▲ 27.5%
lowest -€25,208 (2024)
€15,264▲ €40,472
peak €334,157 (2021)
€284,725▼ 1.6%
€142,260▲ 30.9%
peak 2.7 FTE (2024)
1.9 FTE▼ 29.6%
Board5 names since 2018
1 director
Owners
100%
Documentsfilings and deeds
01-07-202630 days before the deadline
2025abbreviated format
Gross margin from €88,665 to €113,032Back to profit: €15,264Staff from 2.7 FTE to 1.9 FTERegistered office moved from Wavre to Etterbeek 24-01Dividend €20,000Debts from €108,713 to €142,260

Key points

from the 2025 annual accounts

Equity

€284,725 ▼ 1.6%
289,4612024+15,264Profit-20,000Dividend284,7252025

MAXPHARMA paid out €20,000 in dividends. That is 131% of the 2025 profit.

Staff

2 employees on 31-12-2025
432021462022432023542024232025

In 2025, 2 people joined and 3 left.

Filings

26 annual accounts since 2000
AprilJune31 JulyOctober200020102020

Five of the last ten came late. The 2022 accounts came latest: 452 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 17,044 companies had the same profile as MAXPHARMA has now. Each dot stands for 43 companies, two years later.

94.3%
were still trading
5.0%
stopped another way
0.5%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 30% or more
  • a profit under 5% of the balance sheet

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 17,044 companies, not a prediction for MAXPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Managing director,
  • 100%score equity €141,142 (2025) · 2025 annual accounts of

Shares in 1 company,

Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0471830863
Registered office moved from Wavre to Etterbeek New registered office: chaussée de Wavre n°736, 1040 ETTERBEEK · Previous registered office: rue des Templiers 73, 1301 Wavre · Resignation: (managing director) · General meeting of 01-01-2025 · Gazette deed
New managing director appointed, resigned · Permanent representative: · Director discharge: · General meeting of 10-02-2022 · Gazette deed
Resignation: (managing director) General meeting of 07-05-2021 · Gazette deed
All 42 events

Comparable companies

same main activity, similar in size and age
Company
MAXPHARMA Etterbeek €426,986 €113,032 66.7% 1.9
APOTHEEK MEES NIEUWRODE Holsbeek €441,980 €134,117 -1.5% 1.9
OFFIPHARMA Froidchapelle €399,757 €124,712 65.3% 1.5
COBEA PHARMA Villers-la-Ville €362,823 €144,021 40.4% 2
APOTHEEK MEES HAACHT STATION Haacht €499,951 €137,247 37.9% 1.6
POGGE Schaerbeek €285,910 €128,031 34.5% 2
PHARMACIE DERASSE La Louvière €387,571 €148,815 26.6% 1.8

These companies have the same main activity as MAXPHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €286,000 and €500,000, founded between 2001 and 2005.

Official details

Source: KBO
Status
Active since 05-05-2000Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Joint committee
313Pharmacies and pricing offices · annual accounts 2025
Establishment unit
2.098.675.3701040 Etterbeek, since 18-12-2001
Financial year end
31 December
Peppol
Reachable since 18-12-2025
Company details

Annual accounts 2025

€113,032▲ 27.5%
≈ €530,000estimated
€15,264
€284,725▼ 1.6%
€426,986▲ 7.2%
Employeeson 31-12-2025
2▼ 60.0%
Filing
Filed on 01-07-2026, 30 days before the end of the filing period
Financials

Insights on MAXPHARMA

MAXPHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €78,126 in 2006 to €113,032 in 2025.

holds all the shares. In January 2025, the Official Gazette published the appointment of as managing director.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette.

Financials

Annual accounts 2025

abbreviated format, filed on 01-07-2026, 30 days before the deadline
€113,032
▲ 27.5%
€28,482
▲ €53,039
€15,264
▲ €40,472
€231,668
▼ 0.4%
66.7%
▼ 6.0 percentage points
2.63
▼ 0.51

The turnover shown is an estimate from the gross margin.

Turnover ≈ €530,000. Estimated: probably between €360,000 and €990,000.

Balance sheet

balance sheet total €426,986 on 31-12-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

Compare with sector

66.7%

Higher than 80% of 13,234 companies in 2025.

2.63

Higher than 73% of 13,093 companies in 2025.

3.6%

Higher than 46% of 13,156 companies in 2025.

MAXPHARMA Middle half of the sector 80% of the sector Abbreviated accounts in retail trade (NACE 47)

Net result: middle half · Equity: middle half · Balance sheet total: bottom quarter · Working capital: middle half · Staff: middle half

Staff

€36,441

Staff costs divided by the average number of full-time equivalents.

-1 person

people who joined people who left

In 2025, 2 people joined and 3 left.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend20252024202320222021202020192018201720162015201420132012201120102009200820072006
Balance sheet: assets
20/58 426,986398,174410,618496,985434,404431,552482,022425,859474,981478,086472,953503,903556,742607,352643,145671,388703,433732,853759,020637,805
21/28 53,05857,01372,605106,757129,387155,980177,799360,074379,496406,623424,416445,308465,129489,081511,603533,816550,995572,661595,740513,319
21 39,10552,13965,17478,20991,244104,279117,314-------------
22/27 3,4534,8747,23428,35137,94651,50560,28950,20769,62996,756114,549135,441155,262179,214201,736223,949241,128262,794285,873203,452
22 ---20,80026,00031,20036,40041,60058,60081,069103,557126,046148,527171,009193,491215,973238,455260,937283,419201,901
23 1,1141,7553,3357,55111,94614,90613,0916,2237,4615,2146,2536,2492,9583,5472,7052,3112,6721,8572,4541,551
24 -----5,39910,7981,1842,3693,5544,7383,1473,7774,6585,5405,665----
26 2,3393,1193,899-----------------
27 -------1,2001,2006,919----------
28 10,500-197197197197197309,867309,867309,867309,867309,867309,867309,867309,867309,867309,867309,867309,867309,867
29/58 373,928341,161338,014390,229305,017275,572304,22265,78595,48571,46348,53758,59591,613118,271131,542137,572152,438160,192163,280124,486
3 162,04094,45496,37494,504100,480116,787133,469-------------
30/36 162,04094,45496,37494,504100,480116,787133,469-------------
40/41 93,14085,881100,66951,86356,81948,47772,5073,13352,43743,05139,34154,17079,275111,510122,892126,024140,546137,655151,073112,402
40 83,94464,19267,16416,70253,64543,78064,2643,03552,36543,0352,260--6,48225,0006,99211,25011,25027,58511,250
41 9,19721,68933,50435,1613,1744,6978,24399731637,08054,17079,275105,02897,892119,032129,296126,405123,488101,152
50/53 ----714714714-------------
54/58 118,091160,491140,373170,573143,018107,59497,30160,00043,04728,4136,8454,42512,3376,7618,65011,54811,89222,53712,20712,084
490/1 65733559773,2883,9862,0002312,652--2,351---------
Balance sheet: equity and liabilities
10/49 426,986398,174410,618496,985434,404431,552482,022425,859474,981478,086472,953503,903556,742607,352643,145671,388703,433732,853759,020637,805
10/15 284,725289,461314,670318,569334,157259,130268,228228,917146,016233,373211,968203,644191,186196,594187,566167,728142,699129,529113,359107,410
10/11 61,97361,97361,97361,97361,97361,97361,97361,97361,973160,973160,973160,973160,97361,97361,97361,97361,97361,97361,97361,973
10 61,97361,97361,97361,97361,973---------------
100 61,97361,97361,97361,97361,97361,97361,97361,97361,973160,973160,973160,973160,97361,97361,97361,97361,97361,97361,97361,973
13 6,1976,1976,1976,19717,69717,69743,69743,69743,69742,09742,09716,0976,9676,1976,1976,1976,1976,1976,1976,197
130/1 6,1976,1976,1976,1976,1976,197--------------
130 6,1976,1976,1976,1976,1976,1976,1976,1976,19716,09716,09716,0976,9676,1976,1976,1976,1976,1976,1976,197
133 ----11,50011,50037,50037,50037,50026,00026,000---------
14 216,555221,291246,499250,398254,486179,459162,558123,24740,34530,3028,89726,57323,245128,423119,39699,55774,52861,35945,18839,239
17/49 142,260108,71395,949178,416100,247172,422213,793196,942328,965244,713260,985300,260365,556410,758455,579503,660560,734603,323645,661530,395
17 -----37,67148,67655,06969,760100,708129,399155,689199,721244,247297,409352,025401,458446,121487,922426,108
170/4 -----37,67148,67655,06969,760100,708129,399155,689199,721244,247297,409352,025401,458446,121487,922426,108
42/48 142,260108,61795,949178,416100,247134,751164,999141,873259,205144,005131,138142,186159,520159,449158,170151,635157,568153,209142,172102,451
42 -----11,51511,26316,43330,62430,19530,36241,43055,47853,15751,00748,75744,66341,80139,40833,836
43 -------739---7,5262,5412,532------
430/8 -------739---7,5262,5412,532------
44 116,77293,99963,242144,33574,10071,79485,1122,6041,2791,840570199377511,7939662,91565462,077
440/4 116,77293,99963,242144,33574,10071,79485,1122,6041,2791,840570199377511,7939662,91565462,077
45 4,22913,99732,61122,27126,14710,73530,02417,7027,20615,5638,6982325,2197,8039,2882,6783,86010,83513,79421,757
450/3 2981,1067,4708,8008,1182,70914,30917,7027,20615,5638,6982325,2197,8039,2882,6783,86010,83513,79414,472
454/9 3,93112,89125,14113,47118,0298,02615,715------------7,285
47/48 21,2596219511,810-40,70738,600104,395220,09596,40891,50892,97995,34595,20896,08299,233106,13199,92088,96444,782
492/3 -96----118---4482,3856,3147,062--1,7083,99315,5681,836
Income statement
9900 113,03288,665127,530123,758225,463148,964191,267119,23750,25562,57255,62156,66059,51166,37786,71097,49487,97093,56093,84978,126
62 69,23897,521108,368100,31694,72493,146104,773-------------
630 14,91215,39417,25022,63027,94526,53327,5387,62324,89224,71224,80624,13123,95223,95223,80923,47322,84423,07937,89117,729
640/8 400305314217-13214--3,084--2,274----89179
66A --1,300-----------------
9901 28,482-24,556298594102,79329,28458,953111,40125,36337,86027,73132,52935,55940,15162,90174,02165,12770,48155,86960,217
75/76B -1,1524011,13445174295163221164937165132128183237360307
75 -1,1524011,13445174295163221164937165132128183237360307
65/66B 3,3651,8041,2481,2273,2482,2505,4085,0728,4978,86513,12415,97316,75819,71824,59128,03036,68237,68136,95931,411
65 3,3651,8041,2481,2273,2482,2505,4085,0728,4978,86513,12415,97316,75819,71824,59128,03036,68237,68136,95931,411
9903 25,117-25,208-55050199,59027,20953,840106,34516,89829,01714,62416,60518,83820,59838,44346,11928,62833,03719,27129,113
67/77 9,853-3,3504,58924,56410,30714,52923,4435,2557,6116,3004,1485,1903,51410,54813,0337,4038,8115,2667,102
9904 15,264-25,208-3,900-4,08875,02716,90239,31182,90211,64321,4058,32412,45813,64817,08427,89433,08621,22524,22614,00522,011
9905 15,264-25,208-3,900-4,08875,02716,90239,31182,90211,64321,4058,32412,45813,64817,08427,89433,08621,22524,22614,00522,011
Appropriation of the result
9906 236,555221,291246,499250,398254,486179,459162,558123,24741,94530,30234,89735,703142,071136,479127,452107,61382,58469,41553,24450,295
14P 221,291246,499250,398254,486179,459---------------
791/2 ---11,500-26,000--9,900-----------
691/2 --------11,500-26,0009,130770-------
6920 -----------9,130770-------
6921 --------11,500-26,000---------
694/7 20,000--11,500-26,000------118,0568,0568,0568,0568,0568,0568,05611,056
694 20,000--11,500-26,000------118,0568,0568,0568,0568,0568,0568,0568,056
695 -------------------3,000
Social balance sheet
9087 1.92.72.32.32.32.12.1-------------
Hours worked1013 2,0363,4363,8964,0913,9323,6453,730-------------
Document PDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDF

The accounts for 6 older financial years (2000-2005) were filed as documents without figures as data, scans for example.

The notes to these accounts have 9 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 01-07-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-12-2025 abbreviated format 01-07-2026 2026-00244760 PDF
31-12-2024 full format 24-07-2025 2025-00303307 PDF
31-12-2023 full format 23-08-2024 2024-00379257 PDF
31-12-2022 abbreviated format 25-10-2024 2024-00516893 PDF
31-12-2021 full format 13-07-2022 2022-20191263 PDF
31-12-2020 full format 31-08-2021 2021-62200565 PDF
31-12-2019 full format 30-06-2020 2020-25200574 PDF
31-12-2018 micro format 29-08-2019 2019-60900473 PDF
31-12-2017 full format 13-08-2018 2018-45700107 PDF
31-12-2016 full format 06-07-2017 2017-28500041 PDF
31-12-2015 full format 30-08-2016 2016-57800304 PDF
31-12-2014 full format 24-08-2015 2015-47700377 PDF
31-12-2013 full format 15-09-2014 2014-58600253 PDF
31-12-2012 full format 29-08-2013 2013-54800531 PDF
31-12-2011 full format 27-06-2012 2012-25000244 PDF
31-12-2010 full format 31-08-2011 2011-53700237 PDF
31-12-2009 full format 24-08-2010 2010-44600204 PDF
31-12-2008 full format 28-08-2009 2009-70400008 PDF
31-12-2007 full format 26-08-2008 2008-69500015 PDF
31-12-2006 full format 11-09-2007 2007-72100030 PDF
31-12-2005 full format 21-08-2006 2006-64700511 PDF
31-12-2004 full format 08-07-2005 2005-44705124 PDF
31-12-2003 full format 22-10-2004 2004-74703687 PDF
31-12-2002 full format 25-08-2003 2003-62801756 PDF
31-12-2001 full format 06-09-2002 2002-53805076 PDF
31-12-2000 full format 11-10-2001 2001-63600738 PDF

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend20252024202320222021202020192018201720162015201420132012201120102009200820072006
43,394-9,16217,54823,224130,73955,81886,491119,02350,25562,57252,53756,66059,51164,10386,71097,49487,97093,56093,76077,946
30,176-9,81413,35118,543102,97243,43566,84990,52436,53546,11733,13036,58937,60041,03651,70356,55944,06947,30551,89639,740
10,956-1973,89901,3524,715939,572-11,8003,4856,9193,9144,31001,4301,5966,2941,1770120,3121,998
-42,40020,118-30,20027,55635,42410,29337,30116,95314,63521,5672,420-7,9125,577-1,889-2,898-344-10,64510,330123-
231,668232,544242,065211,813204,770140,821139,223-76,087-163,720-72,542-82,601-83,591-67,908-41,179-26,628-14,063-5,1306,98221,10822,035
66.7%72.7%76.6%64.1%76.9%60.0%55.6%53.8%30.7%48.8%44.8%40.4%34.3%32.4%29.2%25.0%20.3%17.7%14.9%16.8%
2.633.143.522.193.042.051.840.460.370.500.370.410.570.740.830.910.971.051.151.22
1.492.272.521.662.041.181.030.460.370.500.370.410.570.740.830.910.971.051.151.22
0.500.380.300.560.300.670.800.862.251.051.231.471.912.092.433.003.934.665.704.94
5.4%-8.7%-1.2%-1.3%22.5%6.5%14.7%36.2%8.0%9.2%3.9%6.1%7.1%8.7%14.9%19.7%14.9%18.7%12.4%20.5%
3.6%-6.3%-0.9%-0.8%17.3%3.9%8.2%19.5%2.5%4.5%1.8%2.5%2.5%2.8%4.3%4.9%3.0%3.3%1.8%3.5%
12.89-5.0814.0618.9340.26---------------

EBIT margin: not included in this filing.

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Social balance sheet

Item31-12-202531-12-202431-12-202331-12-202231-12-2021
Employees at the balance-sheet date25435
full-time----1
part-time25434
in full-time equivalents1.42.62.523.5
1.42.72.32.32.3
On a permanent contract24334
Joined25444
Left34363

Source: social balance sheet in the 2021 to 2025 annual accounts

Investments

fixed assets acquired
Item20252024202320222021
Tangible fixed assets€456-€3,899-€1,352
Financial fixed assets€10,500----
€14,912€15,394€17,250€22,630€27,945

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Insights on MAXPHARMA

The operating result for 2025 is a profit of €28,482, after a loss of €24,556 in 2024. It is the highest result since 2021.

Debt's share of the balance-sheet total rises from 27.3% to 33.3%. Equity is lower and debt is higher.

Board & ownership

Board

1 director, 1 in day-to-day management, last change in 2025
Managing director, permanent representative
managing director since 01-01-2025 managing director appointed by deed of 24-01-2025
listed in the 2025 annual accounts, filed on 01-07-2026
Permanent representatives 1
Permanent representative, for
appointed by deed of 24-01-2025

Office holders in the KBO →

Mandates through the years

5 names, the dashed line is today

Managing director

Managing director

Managing director

Managing director

Managing director
LeadershipBoardEarliermandate already running before its first mentionend not dated
Mandates as a list
    • Managing director, since before 31-12-2024
    • Managing director, appointed by deed of 24-01-2025, still in office
    • Managing director, from 02-05-2018 to 24-01-2025
    • Managing director, appointed by deed of 18-03-2022, until 24-01-2025
    • Director, from before 02-05-2018 to 18-03-2022
    • Managing director, from before 02-05-2018 to 18-03-2022
    • Managing director, from 02-05-2018 to 30-07-2021
    • Director, from before 02-05-2018, last mentioned in 2018
    • Managing director, from before 02-05-2018, last mentioned in 2018

See the board, name and registered office on a given date →

Control

Parent
Equity €141,142
Profit €42,183 in 2025
Checked score
Source: accounts 2025
100%
This company
MAXPHARMA
Equity €284,725
Profit €15,264 in 2025

Capital

Capital
€61,973.38
Shares
250 in the deed of 05-02-2018
Source
deed of 05-02-2018

Owners through the years

as the annual accounts name them
consolidates100%
100%
Owners as a list

Source: parent in its own accounts, lists of holdings in the owners' accounts

Capital transactions

Capital over time
  1. 05-02-2018 Capital reduction of €99,000 · to €61,973.38 · repaid to the shareholders
  2. 05-02-2018 Incorporation · BEF 2,500,000 · 250 shares
  3. 05-02-2018 Capital increase of €99,000 · to €160,973.38 · 396 new shares · in cash

Network & group

Holdings

own 2020 accounts
This companyMAXPHARMA1 holding, 1 country 2020 accounts

Belgium 1 Equity Result

  • BE no longer active -€24,846 result €15,725

Source: list of holdings in its own 2020 accounts. The amounts are in that list and come from the holdings' accounts at 31-12-2011, in their own currency.

Parent

Belgium · 100% of the shares · equity €141,142 · profit €42,183 (2025)
Checked score

Earlier ties

via , at MAXPHARMA until 2022 · Permanent representative · deed of 18-03-2022
founded in 2022
 total assets €181,884 (2025)

Holdings and subsidiaries

1 holding

Holdings 1

Share, source and own figures per holding (1)
Holdings through the years 2006 to 2020
Holdings through the years
Name200620072008200920102011201220132014201520162017201820192020
100%

Source: list of holdings in its own accounts

Acquisitions and mergers

1 transaction
Took over:MAXPHARMA
BE 0431.520.831Gazette deed of 29-01-2019 (4 deeds) · effective 01-10-2018

Connections & network

Depth

The network starts from the earlier ties.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.

Timeline

Timeline

42 events since 2000

Deadline for the 2026 accounts: 31-07-2027

2026
Annual accounts 2025 filed NBBabbreviated format · 30 days before the deadline
2025
Back to profit net €15,264 The net result is €15,264, after 3 loss-making years.
Registered in the Peppol Directory Reachable for e-invoices through 0208:0471830863
Annual accounts 2024 filed PDFfull format · 7 days before the deadline
Registered office moved from Wavre to EtterbeekNew registered office: chaussée de Wavre n°736, 1040 ETTERBEEK · Previous registered office: rue des Templiers 73, 1301 Wavre · Resignation: (managing director) · General meeting of 01-01-20256 points ▸
  • General meeting, 01-01-2025
  • Director resignation, (managing director)
  • Permanent representative,
  • Director appointment, (managing director)
  • Permanent representative,
  • Registered-office move, chaussée de Wavre n°736, 1040 ETTERBEEK

Open the deed in the Belgian Official Gazette

2024
Weakest financial year net -€25,208 The net result drops to -€25,208, the lowest from 2006 to 2025. It recovers the following year.
Annual accounts 2022 filed PDFabbreviated format · 452 days late
Annual accounts 2023 filed PDFfull format · 23 days late
2022
Annual accounts 2021 filed PDFfull format · 18 days before the deadline
New managing director appointed, resigned · Permanent representative: · Director discharge: · General meeting of 10-02-20225 points ▸
  • General meeting, 10-02-2022
  • Director resignation, (managing director)
  • Director discharge,
  • Director appointment, (managing director)
  • Permanent representative,
  • The deed holds 1 more point.

Open the deed in the Belgian Official Gazette

2021
Annual accounts 2020 filed PDFfull format · 31 days late
Resignation: (managing director)General meeting of 07-05-20212 points ▸
  • General meeting, 07-05-2021
  • Director resignation, (managing director)

Open the deed in the Belgian Official Gazette

2020
Annual accounts 2019 filed PDFfull format · 31 days before the deadline
2019
Liquidity more than triples current ratio 1.84 The current ratio rises from 0.46 to 1.84.
Annual accounts 2018 filed PDFmicro format · 29 days late
Merger: GEHELULE takes over MAXPHARMACompany renamed from GEHELULE to MAXPHARMA · Resignation: (manager) · The company holds all the shares of MAXPHARMA · General meeting of 10-01-20197 points ▸
  • General meeting, 10-01-2019, mentioned twice in the deed
  • The company holds all the shares of MAXPHARMA
  • Accounting effect, 01-01-2019
  • Name change, MAXPHARMA
  • Director resignation, (manager)
  • Director discharge, (gérante de la société absorbée)
  • Power of attorney,
  • The deed holds 9 more points.

Open the deed in the Belgian Official Gazette

2018
Highest result from 2006 to 2025 net €82,902 ▲612% The operating result of €111,401 and the net result of €82,902 are both a record.
Merger proposal: GEHELULE takes over MAXPHARMAThe company holds all the shares of MAXPHARMA2 points ▸
  • Accounting effect, 01-01-2019
  • The company holds all the shares of MAXPHARMA
  • The deed holds 3 more points.

Open the deed in the Belgian Official Gazette

Annual accounts 2017 filed PDFfull format · 13 days late
Reappointments: (managing director) and (managing director)General meeting of 06-06-20186 points ▸
  • General meeting, 06-06-2018
  • Director reappointment,
  • Director reappointment,
  • Board meeting, 06-06-2018
  • Director reappointment, (managing director)
  • Director reappointment, (managing director)
  • The deed holds 1 more point.

Open the deed in the Belgian Official Gazette

Capital increaseCapital from €160,973.38 to €61,973.38 · Capital from €61,973.38 to €160,973.38, 396 new shares · Founding capital of BEF 2.500.000, 250 shares · General meeting of 22-12-20176 points ▸
  • General meeting, 22-12-2017
  • Incorporation, 05-05-2000
  • Capital decrease, €99,000
  • Amendment of the articles, article 5
  • Founding capital, BEF 2.500.000, 250 shares
  • Capital increase, €99,000

Open the deed in the Belgian Official Gazette

2017
Annual accounts 2016 filed PDFfull format · 25 days before the deadline
2016
Annual accounts 2015 filed PDFfull format · 30 days late
2015
Annual accounts 2014 filed PDFfull format · 24 days late
2014
Equity above €200,000 equity €203,644 ▲6.5% Equity rises from €191,186 to €203,644.
Annual accounts 2013 filed PDFfull format · 46 days late
2013
Annual accounts 2012 filed PDFfull format · 29 days late
2012
Annual accounts 2011 filed PDFfull format · 34 days before the deadline
2011
Annual accounts 2010 filed PDFfull format · 31 days late
2010
Equity above €150,000 equity €167,728 ▲17.5% With a profit in every financial year since 2006, equity grows to €167,728.
Annual accounts 2009 filed PDFfull format · 24 days late
2009
Annual accounts 2008 filed PDFfull format · 28 days late
2008
Annual accounts 2007 filed PDFfull format · 26 days late
2007
Annual accounts 2006 filed PDFfull format · 42 days late
2006
Annual accounts 2005 filed PDFfull format
2005
Annual accounts 2004 filed PDFfull format
2004
Annual accounts 2003 filed PDFfull format
2003
Annual accounts 2002 filed PDFfull format
2002
Annual accounts 2001 filed PDFfull format
2001
First establishment Steenweg op Waver 736, Etterbeek
Annual accounts 2000 filed PDFfull format
2000
Incorporation published on 17-05-2000

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official GazetteFilings with the National Bank

History

On 5 May 2000, MAXPHARMA was incorporated.1 A capital increase in 2018 brought the capital to €160,973.2 MAXPHARMA was merged into the company in 2018.3 In 2025 the registered office moved to Etterbeek.4 Total assets went from €425,859 in 2018 to €426,986 in 2025 and headcount from 2.1 full-time equivalents in 2019 to 1.9 in 2025.5

  1. 1KBO register
  2. 2Belgian Official Gazette, 05-02-2018
  3. 3Belgian Official Gazette, 29-01-2019
  4. 4Belgian Official Gazette, 24-01-2025
  5. 5National Bank, annual accounts 2018, 2019 and 2025

Company details

Identity

Enterprise number
0471.830.863
VAT number
BE 0471.830.863
Peppol ID
0208:0471830863
Other Peppol ID
9925:BE0471830863
LEI code
699400ON9IPNJ9OGHP16 no longer live in the LEI register
Legal form
Public limited company
Status
Active, normal situation
Founded
05-05-2000
Financial year
ends on 31 December
Peppol
Reachable since 18-12-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
Name
MAXPHARMA in French
Former name
GEHELULE until 10-01-2019 · deed of 29-01-2019
Entity type
Legal entity

Activities

NACEBEL 2025
VAT activities
47730 Retail sale of pharmaceutical products main activity
Social security (RSZ) activities
47730 Retail sale of pharmaceutical products main activity
Joint committees annual accounts 2025
JC 313 Pharmacies and pricing offices
Codes under NACEBEL 2008
VAT activities
47730 Retail trade main activity
Social security (RSZ) activities
47730 Retail trade main activity
PurposeThe purpose describes the activities the company may carry out under its articles.
“Toutes opérations généralement quelconques, industrielles, commerciales, financières, mobilières ou immobilières se rapportant directement…”
Text of the purpose

“Toutes opérations généralement quelconques, industrielles, commerciales, financières, mobilières ou immobilières se rapportant directement aux activités d'exploitation d'officines pharmaceutiques, homéopathiques et de bandagisteries, ainsi que la fabrication et la commercialisation de produits pharmaceutiques, homéopathiques et cosmétologiques.”

deed of 05-11-2018 (in French)

Registered office and establishments

1 establishment
Establishment Since Unit numberFASFC approval
Steenweg op Waver 736 registered office 1040 Etterbeek 18-12-2001 2.098.675.370 Pharmacy (food >3 months)
1 former office
  • rue des Templiers 73, 1301 Wavre until 01-01-2025 · deed of 24-01-2025

Buildings and parcels at the address

Ground area
94 m²
Buildings
106 m²
Volume, LiDAR
1,238 m³
Tallest building
16.4 m
Buildings to scale, each on its own parcel
106 m², 16.4 m 106 m², 16.4 m

Location

registered office establishment The establishment unit on the map

Parcels

Cadastral parcelArea Buildings Height / floors
21362B0061/00A00294 m² 1 · 106 m² 16.4 m · 5

Recognitions

Food safety, FASFC

1 site
Etterbeekunit number 2.098.675.370
1 permission
Pharmacy (food >3 months) · since 01-01-2022

Source: FAVV-AFSCA, open data, updated on 02-11-2026

We would like to set cookies. That happens only with your consent. What we measure